The pharmaceutical industry's support from governments during the pandemic, particularly when developing vaccines, has gone; in its place are more regulations aimed at improving access to medicines and multiple instances of cost containment both in and outside the European Union.
Coupled with broader macroeconomic trends and evolving threats such as cyber-attacks, it adds up to a bleak outlook for the sector. To help pharmaceutical manufacturers tackle these challenges, we commissioned an in-depth report to understand what the obstacles are and what they mean for the future of the sector. In this paper, discover:
The five major challenges facing pharma manufacturers
How they can be tackled
Please fill out the form to download the white paper.
